A CCLG/Cancer Research UK Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) Given for 72 Hours Every 21 Days Via Intravenous Infusion in Children and Adolescents With Relapsed and Refractory Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2017
At a glance
- Drugs AT 9283 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 08 Feb 2017 Results of population model of AT9283 developed from the data of phase I trials of AT9283 (NCT00443976, NCT00522990, NCT00985868 and NCT01431664) published in the British Journal of Clinical Pharmacology.
- 06 Jun 2015 Accrual to date is 100% according to United Kingdom Clinical Research Network.
- 17 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.